Trial
NCT04501094
A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Urothelial Cancer
Intervention
Bintrafusp alfa (M7824)
Why stopped
Because of the low accrual and the safety concerns we closed the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-03-22